Cancer Treatment Centers of America Selects WIRB-Copernicus Group
WIRB-Copernicus Group announced that it has been chosen by Cancer Treatment Centers of America to expand its clinical research program.
WIRB-Copernicus Group (WCG), a global provider of regulatory and ethical review services and software to support clinical research, announced that it has been chosen by Cancer Treatment Centers of America® (CTCA) to expand its clinical research program. WCG will assist CTCA in the centralization and optimization of its regulatory and ethical review process, allowing CTCA to manage a higher volume of cutting-edge research while maintaining participant protection. CTCA is a leader in integrative cancer care with a national network of five state-of-the-art hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.WCG was chosen for its experience in reviewing oncology research, and WCG Oncology™, WCG’s oncology-focused oversight division, will partner with CTCA in its expansion process.
Read the full release here.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
